Eli Lilly Announces Acquisition of CAR-T Gene Therapy Firm, Leading to Stock Decline
Eli Lilly (LLY) announced a $7 billion acquisition of Kelonia Therapeutics to expand into CAR-T gene therapy, but its stock fell 2.5% despite positive analyst commentary. The move aims to diversify the company away from its reliance on GLP-1 drugs, though investors reacted negatively to the news.
Tickers: $LLY
Topics: CAR-T gene therapy Eli Lilly GLP-1 drugs Kelonia Therapeutics stock price movement